Chenevix-Trench G - Search Results

1

Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.

Pearce CL, Wu AH, Gayther SA, Bale AE; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group; Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A; Ovarian Cancer Association Consortium. Pearce CL, et al. Br J Cancer. 2008 Jan 29;98(2):282-8. doi: 10.1038/sj.bjc.6604170. Epub 2008 Jan 22. Br J Cancer. 2008. PMID: 18219286 Free PMC article.

2

Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci.

Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG. Chenevix-Trench G, et al. Am J Hum Genet. 1992 Dec;51(6):1377-85. Am J Hum Genet. 1992. PMID: 1361101 Free PMC article.

3

Further evidence for an association between genetic variation in transforming growth factor alpha and cleft lip and palate.

Chenevix-Trench G, Jones K, Green A, Martin N. Chenevix-Trench G, et al. Am J Hum Genet. 1991 May;48(5):1012-3. Am J Hum Genet. 1991. PMID: 1673285 Free PMC article. No abstract available.

4

Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.

Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BA, Gayther SA. Foster KA, et al. Cancer Res. 1996 Aug 15;56(16):3622-5. Cancer Res. 1996. PMID: 8705994

5

Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas.

Chenevix-Trench G, Coombs T, Kerr J, Purdie D, Green A, Cummings MC. Chenevix-Trench G, et al. J Natl Cancer Inst. 1997 Jun 18;89(12):890-1. doi: 10.1093/jnci/89.12.890. J Natl Cancer Inst. 1997. PMID: 9196259 No abstract available.

6

Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.

Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung SW, Lee JB, Kerr J, Chenevix-Trench G, Kim S, Barrett JC, Koi M. Choi C, et al. Genes Chromosomes Cancer. 1997 Nov;20(3):234-42. Genes Chromosomes Cancer. 1997. PMID: 9365830

7

Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer.

Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G. Webb PM, et al. J Natl Cancer Inst. 1998 Nov 18;90(22):1729-34. doi: 10.1093/jnci/90.22.1729. J Natl Cancer Inst. 1998. PMID: 9827528

8

CYP17 promotor polymorphism and ovarian cancer risk.

Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 May 1;86(3):436-9. doi: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a. Int J Cancer. 2000. PMID: 10760835 Free article.

9

Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer.

Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 Sep 1;87(5):637-43. Int J Cancer. 2000. PMID: 10925355 Free article.

10

Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 Jan;22(1):67-72. doi: 10.1093/carcin/22.1.67. Carcinogenesis. 2001. PMID: 11159743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

569 results

Search Page